Piclozotan

Piclozotan (SUN-N4057) is a selective 5-HT_1A receptor partial agonist, which has neuroprotective effects in animal studies.[1] It has been through early clinical trials in humans for treatment of acute stroke, but results have not yet been announced.[2][3]

Piclozotan

Legal status
Legal status	In general: uncontrolled
Identifiers
IUPAC name 3-chloro-4-[4-[4-(2-pyridinyl)-1,2,3,6-tetrahydropyridin-1-yl]butyl]-1,4-benzoxazepin-5(4H)-one
CAS Number	182415-09-4^Y
PubChem CID	9801640
ChemSpider	7977402^N
UNII	FQE44HS7AH
Chemical and physical data
Formula	C23H24ClN3O2
Molar mass	409.91 g·mol^−1
3D model (JSmol)	Interactive image
SMILES C1CN(CC=C1C2=CC=CC=N2)CCCCN3C(=COC4=CC=CC=C4C3=O)Cl
InChI InChI=1S/C23H24ClN3O2/c24-22-17-29-21-9-2-1-7-19(21)23(28)27(22)14-6-5-13-26-15-10-18(11-16-26)20-8-3-4-12-25-20/h1-4,7-10,12,17H,5-6,11,13-16H2^N Key:URMTUEWUIGOJBW-UHFFFAOYSA-N^N
^NY (what is this?)  (verify)

See also

• Repinotan
• Robalzotan

References

1. Kamei K, Maeda N, Nomura K, Shibata M, Katsuragi-Ogino R, Koyama M, et al. (March 2006). "Synthesis, SAR studies, and evaluation of 1,4-benzoxazepine derivatives as selective 5-HT1A receptor agonists with neuroprotective effect: Discovery of Piclozotan". Bioorganic & Medicinal Chemistry. 14 (6): 1978–92. doi:10.1016/j.bmc.2005.10.046. PMID 16290165.
2. Ferro JM, Dávalos A (2006). "Other neuroprotective therapies on trial in acute stroke". Cerebrovascular Diseases. 21 Suppl 2 (2): 127–30. doi:10.1159/000091712. PMID 16651823.
3. Mondick JT, Oo C, Patel D, Fujitani T, Shimizu K, Barrett JS (2009). "Population pharmacokinetics of the selective serotonin 5-HT1A receptor partial agonist piclozotan". American Journal of Therapeutics. 16 (2): 106–15. doi:10.1097/MJT.0b013e31816b8c85. PMID 19300037.